Tier A · Established human benefit
Liraglutide
An earlier GLP-1 peptide that helped establish the modern metabolic-therapy era.
Why researchers care
Potential human relevance
- Improved glycemic control in type 2 diabetes
- Clinically meaningful weight reduction in obesity treatment
- Longstanding human safety and efficacy experience
What the human evidence says
Evidence, not extrapolation
Liraglutide has large human trial programs and years of approved clinical use. It is less potent for weight reduction than newer incretin therapies, but its evidence is mature and instructive.
How to think about it
The Yooper Peptides take
Liraglutide is important historically: it helped prove that peptide-based incretin signaling could be used as a durable metabolic treatment strategy.
Primary / authoritative reading